Thymosin a1 use is not associated with reduced COVID-19 mortality.

Plain Language Summary

This study reports that thymosin alpha-1 use was not associated with reduced mortality in COVID-19 patients. The finding adds to the mixed evidence regarding the peptide's effectiveness as a treatment for severe coronavirus disease.